Saturday 17 October 2026
Export ROIV’s income statement to Excel — free account
Roivant Sciences Ltd.
ROIV Healthcare Biotechnology
In the quarter to June 2026, revenue fell 33.6%, EPS grew 21.2% and free cash flow fell 30.0%, each against the same quarter a year earlier.
33.53
0.51
−1.50%
Follow ROIV
Roivant Sciences Ltd. (ROIV) P/E ratio
Roivant Sciences Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 2.2× (April 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 1.9× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 21 more quarters | Free account |
Against its own ten years
Low 0.0×
High 2.2×
Ten-year median
0.0×
Current reading's percentile
83
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ROIV Roivant Sciences Ltd. | n/m |
| BNTX BioNTech SE Sponsored ADR compare | n/m |
| INSM Insmed, Inc. compare | n/m |
| INCY Incyte Corporation compare | 13.9× |
| EXEL Exelixis, Inc. compare | 18.8× |
| GMAB Genmab A/S Sponsored ADR compare | 29.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 39.5× |
| RPRX Royalty Pharma PLC compare | 42.3× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 62.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)